Article CommentaryCommentary

A Strategic Guide to Improve and De-Risk Vaccine Development: CEPI’s CMC Framework

Anna Särnefält, Ranna Eardley-Patel, Diletta Magini, Vishal Sonje, Antonio Guzzi, Renske Hesselink, Matthew Scotney, Alessandro Lazdins, Valerie Chambard, Christof Vinnemeier and Ingrid Kromann
PDA Journal of Pharmaceutical Science and Technology September 2024, 78 (5) 613-623; DOI: https://doi.org/10.5731/pdajpst.2023.012912

Article Information

vol. 78 no. 5 613-623
DOI 
https://doi.org/10.5731/pdajpst.2023.012912
PubMed 
39054065
Published By 
Parenteral Drug Association (PDA)
Print ISSN 
1079-7440
Online ISSN 
1948-2124
History 
  • Published online October 22, 2024.

Article Versions

Copyright & Usage 
© PDA, Inc. 2024

Author Information

  1. Anna Särnefält*,
  2. Ranna Eardley-Patel,
  3. Diletta Magini,
  4. Vishal Sonje,
  5. Antonio Guzzi,
  6. Renske Hesselink,
  7. Matthew Scotney,
  8. Alessandro Lazdins,
  9. Valerie Chambard,
  10. Christof Vinnemeier and
  11. Ingrid Kromann
  1. Coalition for Epidemic Preparedness Innovations (CEPI), 0218 Oslo, Norway
  1. ↵* Corresponding Author: Coalition for Epidemic Preparedness Innovations (CEPI), Post box 1030 Hoff, 0218 Oslo, Norway; Telephone: 447827234088; E-mail: anna.sarnefalt{at}cepi.net
View Full Text

Cited By...

Back to top

In This Issue

Print
Download PDF
Article Alerts
Email Article
Citation Tools
A Strategic Guide to Improve and De-Risk Vaccine Development: CEPI’s CMC Framework
Anna Särnefält, Ranna Eardley-Patel, Diletta Magini, Vishal Sonje, Antonio Guzzi, Renske Hesselink, Matthew Scotney, Alessandro Lazdins, Valerie Chambard, Christof Vinnemeier, Ingrid Kromann
PDA Journal of Pharmaceutical Science and Technology Sep 2024, 78 (5) 613-623; DOI: 10.5731/pdajpst.2023.012912
Twitter logo Facebook logo Mendeley logo

Jump to section

Keywords